Cargando…

The Efficacy of Parathyroid Hormone Analogues in Combination With Bisphosphonates for the Treatment of Osteoporosis: A Meta-Analysis of Randomized Controlled Trials

Parathyroid hormone (PTH) analogues increase bone strength primarily by stimulating bone formation, whereas antiresorptive drugs (bisphosphonates) reduce bone resorption. Therefore, some studies have been designed to test the hypothesis that the concurrent administration of the 2 agents would increa...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wan, Chen, Wenjian, Lin, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635737/
https://www.ncbi.nlm.nih.gov/pubmed/26402797
http://dx.doi.org/10.1097/MD.0000000000001156
_version_ 1782399544380620800
author Li, Wan
Chen, Wenjian
Lin, Yang
author_facet Li, Wan
Chen, Wenjian
Lin, Yang
author_sort Li, Wan
collection PubMed
description Parathyroid hormone (PTH) analogues increase bone strength primarily by stimulating bone formation, whereas antiresorptive drugs (bisphosphonates) reduce bone resorption. Therefore, some studies have been designed to test the hypothesis that the concurrent administration of the 2 agents would increase bone density more than the use of either one alone. This meta-analysis aimed to determine whether combining PTH analogues with bisphosphonates would be superior to PTH alone. Electronic databases were searched to identify relevant publications up to March, 2014. Randomized controlled trials (RCTs) comparing PTH analogues combined bisphosphonates with PTH for osteoporosis were analyzed. According to the Cochrane Handbook for systematic Reviews of Interventions 5.2, we identified eligible studies, evaluated the methodological quality, and abstracted relevant data. Totally 7 studies involving 641 patients were included for meta-analysis. The pooled data showed that there were no significant differences in the percent change of spine BMD (MD(1-year) = −0.97, 95% CI −2.81 to 0.86, P = 0.30; MD(2-year) =  − 0.57, 95% CI −5.01 to 6.14, P = 0.84), femoral neck BMD (MD(1-year) = 0.60, 95% CI −0.91 to 2.10, P = 0.44; MD(2-year) = −0.73, 95% CI −4.97 to 3.51, P = 0.74), the risk of vertebral fracture (risk ratio [RR] = 1.27; 95% CI 0.29–5.57; P = 0.75), and the risk of nonvertebral fracture (RR = 0.97; 95% CI 0.40–2.35; P = 0.95) between the 2 groups, whereas combination group improves the percent change of hip BMD at 1 year (MD = 1.16, 95% CI 0.56–1.76; P < 0.01) than PTH analogues group. Our results showed that there was no evidence for the superiority of combination therapy, although significant change was found for hip BMD at 1 year in combination group. Further large multicenter randomized controlled trials are still needed to investigate the efficacy of combination therapy.
format Online
Article
Text
id pubmed-4635737
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-46357372015-11-30 The Efficacy of Parathyroid Hormone Analogues in Combination With Bisphosphonates for the Treatment of Osteoporosis: A Meta-Analysis of Randomized Controlled Trials Li, Wan Chen, Wenjian Lin, Yang Medicine (Baltimore) 6900 Parathyroid hormone (PTH) analogues increase bone strength primarily by stimulating bone formation, whereas antiresorptive drugs (bisphosphonates) reduce bone resorption. Therefore, some studies have been designed to test the hypothesis that the concurrent administration of the 2 agents would increase bone density more than the use of either one alone. This meta-analysis aimed to determine whether combining PTH analogues with bisphosphonates would be superior to PTH alone. Electronic databases were searched to identify relevant publications up to March, 2014. Randomized controlled trials (RCTs) comparing PTH analogues combined bisphosphonates with PTH for osteoporosis were analyzed. According to the Cochrane Handbook for systematic Reviews of Interventions 5.2, we identified eligible studies, evaluated the methodological quality, and abstracted relevant data. Totally 7 studies involving 641 patients were included for meta-analysis. The pooled data showed that there were no significant differences in the percent change of spine BMD (MD(1-year) = −0.97, 95% CI −2.81 to 0.86, P = 0.30; MD(2-year) =  − 0.57, 95% CI −5.01 to 6.14, P = 0.84), femoral neck BMD (MD(1-year) = 0.60, 95% CI −0.91 to 2.10, P = 0.44; MD(2-year) = −0.73, 95% CI −4.97 to 3.51, P = 0.74), the risk of vertebral fracture (risk ratio [RR] = 1.27; 95% CI 0.29–5.57; P = 0.75), and the risk of nonvertebral fracture (RR = 0.97; 95% CI 0.40–2.35; P = 0.95) between the 2 groups, whereas combination group improves the percent change of hip BMD at 1 year (MD = 1.16, 95% CI 0.56–1.76; P < 0.01) than PTH analogues group. Our results showed that there was no evidence for the superiority of combination therapy, although significant change was found for hip BMD at 1 year in combination group. Further large multicenter randomized controlled trials are still needed to investigate the efficacy of combination therapy. Wolters Kluwer Health 2015-09-25 /pmc/articles/PMC4635737/ /pubmed/26402797 http://dx.doi.org/10.1097/MD.0000000000001156 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 6900
Li, Wan
Chen, Wenjian
Lin, Yang
The Efficacy of Parathyroid Hormone Analogues in Combination With Bisphosphonates for the Treatment of Osteoporosis: A Meta-Analysis of Randomized Controlled Trials
title The Efficacy of Parathyroid Hormone Analogues in Combination With Bisphosphonates for the Treatment of Osteoporosis: A Meta-Analysis of Randomized Controlled Trials
title_full The Efficacy of Parathyroid Hormone Analogues in Combination With Bisphosphonates for the Treatment of Osteoporosis: A Meta-Analysis of Randomized Controlled Trials
title_fullStr The Efficacy of Parathyroid Hormone Analogues in Combination With Bisphosphonates for the Treatment of Osteoporosis: A Meta-Analysis of Randomized Controlled Trials
title_full_unstemmed The Efficacy of Parathyroid Hormone Analogues in Combination With Bisphosphonates for the Treatment of Osteoporosis: A Meta-Analysis of Randomized Controlled Trials
title_short The Efficacy of Parathyroid Hormone Analogues in Combination With Bisphosphonates for the Treatment of Osteoporosis: A Meta-Analysis of Randomized Controlled Trials
title_sort efficacy of parathyroid hormone analogues in combination with bisphosphonates for the treatment of osteoporosis: a meta-analysis of randomized controlled trials
topic 6900
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635737/
https://www.ncbi.nlm.nih.gov/pubmed/26402797
http://dx.doi.org/10.1097/MD.0000000000001156
work_keys_str_mv AT liwan theefficacyofparathyroidhormoneanaloguesincombinationwithbisphosphonatesforthetreatmentofosteoporosisametaanalysisofrandomizedcontrolledtrials
AT chenwenjian theefficacyofparathyroidhormoneanaloguesincombinationwithbisphosphonatesforthetreatmentofosteoporosisametaanalysisofrandomizedcontrolledtrials
AT linyang theefficacyofparathyroidhormoneanaloguesincombinationwithbisphosphonatesforthetreatmentofosteoporosisametaanalysisofrandomizedcontrolledtrials
AT liwan efficacyofparathyroidhormoneanaloguesincombinationwithbisphosphonatesforthetreatmentofosteoporosisametaanalysisofrandomizedcontrolledtrials
AT chenwenjian efficacyofparathyroidhormoneanaloguesincombinationwithbisphosphonatesforthetreatmentofosteoporosisametaanalysisofrandomizedcontrolledtrials
AT linyang efficacyofparathyroidhormoneanaloguesincombinationwithbisphosphonatesforthetreatmentofosteoporosisametaanalysisofrandomizedcontrolledtrials